Limited positive predictive value of resistance testing in treatment-experienced patients [2]

AIDS

Volumn 19, Issue 18, 2005, Pages 2178-2179

  Miralles, Diego ^a   Falcon, Ron ^b   Thommes, James ^b  

^a Trimeris Inc   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE;

CELL COUNT; CLINICAL TRIAL; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LETTER; MEDICAL DECISION MAKING; META ANALYSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VIROLOGY; VIRUS LOAD;

EID: 27944464927     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000194131.43382.19     Document Type: Letter

References (6)

1. Panidou EE, Thomas A, Trikalinos JPA, Ioannidis J. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta analysis. AIDS 2004; 18:2153-2161.
2. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, Major JC, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus longitudinal testing approach. J Infect Dis 2005; 191:1325-1330.
3. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
4. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N Engl J Med 2003; 348:2175-2185.
5. Barlett JA, Salgo M, DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients. In: XVth International AIDS Congress. Bangkok, Thailand, 2004 [Poster TuPeB4484].
6. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.